東北大学病院 腫瘍内科｜東北大学大学院医学系研究科・医学部

研究室紹介

研究業績

英文論文 2023年度

  1. Takahashi S，Ouchi K，Sakamoto Y，Mori T，Shimodaira H，Takahashi M，Ohori H，Kudo C，Takahashi Y，Imai H，Akiyama S，Takahashi M，Suto T，Murakawa Y，Oishi T，Isobe H，Okada Y，Kawai S，Yoshioka T，Sato T，Shindo Y，Sugiyama S，Komine K，Chiba N，Okita A，Yamaguchi T，Ishioka C. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. J Gastrointest Oncol 14. 676-691. Apr 29 (2023)
  2. Takahashi S，Sasaki K，Ishioka C. TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease. Breast Cancer (Auckl) 17. 11782234231167655. May 14 (epub) (2023)
  3. Yoshino T，Cervantes A，Bando H，Martinelli E，Oki E，Xu R-H，Mulansari N A，Babu K G，Lee M A，Tan C K，Cornelio G，Chong D Q，Chen L-T，Tanasanvimon S，Prasongsook N，Yeh K-H，Chua C，Sacdalan M D，(Jenson) W J S，Kim S T，Chacko R T，Syaiful R A，Zhang S Z，Curigliano G，Mishima S，Nakamura Y，Ebi H，Sunakawa Y，Takahashi M，Baba E，Peters S，Ishioka C，Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open 8. 101558. Jun (2023)
  4. Wakayama S，Ouchi K，Takahashi S，Yamada Y，Komatsu Y，Shimada K，Yamaguchi T，Shirota H，Takahashi M，Ishioka C. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer. Clin Colorectal Cancer 22. 327-338. Jun 7 (2023)
  5. Osumi H，Takashima A，Ooki A，Yoshinari Y，Wakatsuki T，Hirano H，Nakayama I，Okita N，Sawada R，Ouchi K，Fukuda K，Fukuoka S，Ogura M，Takahari D，Chin K，Shoji H，Kato K，Ishizuka N，Boku N，Yamaguchi K，Shinozaki E. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer. Transl Oncol 35. 101718. Jun 24 (2023)
  6. Kage H，Oda K，Muto M，Tsuchihara K，Okita N，Okuma Y，Kikuchi J，Shirota H，Hayashi H，Kokuryo T，Sakai D，Hirasawa A，Kubo M，Kenmotsu H，Akiyama N，Shinozaki-Ushiku A，Tanabe M，Ushiku T，Miyagawa K，Seto Y. Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan. Cancer Sci 114. 3041-3049. Jul (2023)
  7. Naito Y，Mishima S，Akagi K，Hayashi N，Hirasawa A，Hishiki T，Igarashi A，Ikeda M，Kadowaki S，Kajiyama H，Kato M，Kenmotsu H，Kodera Y，Komine K，Koyama T，Maeda O，Miyachi M，Nishihara H，Nishiyama H，Ohga S，Okamoto W，Oki E，Ono S，Sanada M，Sekine I，Takano T，Tao K，Terashima K，Tsuchihara K，Yatabe Y，Yoshino T，Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors. Int J Clin Oncol 28. 827-840. Jul (2023)
  8. Mishima S，Naito Y，Akagi K，Hayashi N，Hirasawa A，Hishiki T，Igarashi A，Ikeda M，Kadowaki S，Kajiyama H，Kato M，Kenmotsu H，Kodera Y，Komine K，Koyama T，Maeda O，Miyachi M，Nishihara H，Nishiyama H，Ohga S，Okamoto W，Oki E，Ono S，Sanada M，Sekine I，Takano T，Tao K，Terashima K，Tsuchihara K，Yatabe Y，Yoshino T，Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. Int J Clin Oncol 28. 941-955. Aug (2023)
  9. Umegaki S，Shirota H，Kasahara Y，Iwasaki T，Ishioka C. Distinct role of CD8 cells and CD4 cells in antitumor immunity triggered by cell apoptosis using a Herpes simplex virus thymidine kinase/ganciclovir system. Cancer Sci 114. 3076-3086. Aug (2023)
  10. Saijo K，Imai H，Ouchi K，Sasaki K，Yoshida Y，Kawamura Y，Taniguchi S，Kasahara Y，Komine K，Shirota H，Takahashi M，Ishioka C. Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens. Front Oncol 13. 1230731. Aug 16 (2023)
  11. Kobayashi S，Bando H，Taketomi A，Takamoto T，Shinozaki E，Shiozawa M，Hara H，Yamazaki K，Komori K，Matsuhashi N，Kato T，Kagawa Y，Yokota M，Oki E，Komine K，Takahashi S，Wakabayashi M，Yoshino T. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. BMC Cancer 23. 779. Aug 21 (2023)
  12. Fang Z，Li X，Yoshino Y，Suzuki M，Qi H，Murooka H，Katakai R，Shirota M，Pham T A M，Matsuzawa A，Otsuka K，Ishioka C，Mori T，Chiba N. Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation. Cell Rep 42. 112850. Aug 29 (2023)
  13. Ueta R，Imai H，Saijo K，Kawamura Y，Kodera S，Komine K，Ouchi K，Kasahara Y，Taniguchi S，Yoshida Y，Sasaki K，Shirota H，Takahashi M，Ishioka C. Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma. Oncology Oncology 102. 252-259. Sep 14 (Epub) (2023)
  14. Tagami K，Chiu S-W，Kosugi K，Ishiki H，Hiratsuka Y，Shimizu M，Mori M，Kubo E，Ikari T，Arakawa S，Eto T，Shimoda M，Hirayama H，Nishijima K，Ouchi K，Shimoi T，Shigeno T，Yamaguchi T，Miyashita M，Morita T，Inoue A，Satomi E. Cancer Pain Management in Patients Receiving Inpatient Specialized Palliative Care Services. J Pain Symptom Manage Sep 18 (Epub) (2023)
  15. Ando Y，Nishiyama H，Shimodaira H，Takano N，Sakaida E，Matsumoto K，Nakanishi K，Sakai H，Tsukamoto S，Komine K，Yasuda Y，Kato T，Fujiwara Y，Koyama T，Kitamura H，Kuwabara T，Yonezawa A，Okumura Y，Yakushijin K，Nozawa K，Goto H，Matsubara T，Hoshino J，Yanagita M. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28. 1315-1332. Oct (2023)
  16. Mishima S，Naito Y，Akagi K，Hayashi N，Hirasawa A，Hishiki T，Igarashi A，Ikeda M，Kadowaki S，Kajiyama H，Kato M，Kenmotsu H，Kodera Y，Komine K，Koyama T，Maeda O，Miyachi M，Nishihara H，Nishiyama H，Ohga S，Okamoto W，Oki E，Ono S，Sanada M，Sekine I，Takano T，Tao K，Terashima K，Tsuchihara K，Yatabe Y，Yoshino T，Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. Int J Clin Oncol 28. 1237-1258. Oct (2023)
  17. Hiratsuka Y，Tagami K，Inoue A，Sato M，Matsuda Y，Kosugi K，Kubo E，Natsume M，Ishiki H，Arakawa S，Shimizu M，Yokomichi N，Chiu S-W，Shimoda M，Hirayama H，Nishijima K，Ouchi K，Shimoi T，Shigeno T，Yamaguchi T，Miyashita M，Morita T，Satomi E. Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study. Support Care Cancer 31. 632. Oct 16 (Epub) (2023)
  18. Imai H，Saijo K，Kawamura Y，Kodera S，Komine K，Iwasaki T，Takenaga N，Kasahara Y，Ouchi K，Shirota H，Takahashi M，Ishioka C. Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study. Oncology Oct 30 (Epub) Oncology 102. 359-367. (2023)
  19. Taniguchi S H，Komine K，Takenaga N，Yoshida Y，Sasaki K，Kawamura Y，Kasahara Y，Ouchi K，Imai H，Saijo K，Shirota H，Takahashi M，Ishioka C. FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer Res 43. 5699-5704. Dec (2023)
  20. Sunami K，Naito Y，Saigusa Y，Amano T，Ennishi D，Imai M，Kage H，Kanai M，Kenmotsu H，Komine K，Koyama T，Maeda T，Morita S，Sakai D，Hirata M，Ito M，Kozuki T，Sakashita H，Horinouchi H，Okuma Y，Takashima A，Kubo T，Hironaka S，Segawa Y，Yakushijin Y，Bando H，Makiyama A，Suzuki T，Kinoshita I，Kohsaka S，Ohe Y，Ishioka C，Yamamoto K，Tsuchihara K，Yoshino T. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol 10. 95-102. Jan 1 (2024)
  21. Shitara K，Fleitas T，Kawakami H，Curigliano G，Narita Y，Wang F，Wardhani S O，Basade M，Rha S Y，Zamaniah W I W，Sacdalan D L，Ng M，Yeh K H，Sunpaweravong P，Sirachainan E，Chen M-H，Yong W P，Peneyra J L，Ibtisam M N，Lee K-W，Krishna V，Pribadi R R，Li J，Lui A，Yoshino T，Baba E，Nakayama I，Pentheroudakis G，Shoji H，Cervantes A，Ishioka C，Smyth E. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open Jan (2024)
  22. Imai H，Sakamoto Y，Takahashi S，Shibata H，Sato A，Otsuka K，Amagai K，Takahashi M，Yamaguchi T，Ishioka C. Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201). BMC Cancer 24. 262. Feb 24 (2024)
  23. Yoshida Y，Toriyabe S，Imai H，Sasaki K，Kasahara Y，Ouchi K，Saijo K，Onodera K，Ishioka C. Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer. Intern Med Mar 4 (2024)
  24. Imai H，Saijo K，Takenaga N，Komine K，Ouchi K，Kasahara Y，Ishikawa S，Sasaki K，Yoshida Y，Shirota H，Takahashi M，Ishioka C. Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report. Curr Oncol 31. 1477-1482. Mar 12 (2024)